|
|
|
Volumn 143, Issue 23, 2001, Pages 35-
|
|
Results of the VIGOR study. Rofecoxib halves the complication rate;Ergebnisse der VIGOR-Studie. Rofecoxib halbiert die Komplikationsrate.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LACTONE;
NONSTEROID ANTIINFLAMMATORY AGENT;
ROFECOXIB;
SULFONE;
AGED;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
FEMALE;
HUMAN;
MALE;
MIDDLE AGED;
PEPTIC ULCER;
RANDOMIZED CONTROLLED TRIAL;
RHEUMATOID ARTHRITIS;
AGED;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
ARTHRITIS, RHEUMATOID;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
HUMANS;
LACTONES;
MALE;
MIDDLE AGED;
PEPTIC ULCER;
RANDOMIZED CONTROLLED TRIALS;
SULFONES;
|
|
EID: 0035822146
PISSN: 14383276
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|